Australia markets closed

Evoke Pharma, Inc. (EVOK)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.0100-0.0800 (-7.34%)
At close: 03:56PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.0900
Open1.0600
Bid1.0000 x 1000
Ask1.1500 x 1100
Day's range1.0100 - 1.1100
52-week range0.9190 - 5.9600
Volume5,176
Avg. volume12,643
Market cap3.377M
Beta (5Y monthly)0.36
PE ratio (TTM)N/A
EPS (TTM)-2.3100
Earnings date07 Nov 2023 - 13 Nov 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est7.00
  • GlobeNewswire

    Evoke Pharma Receives Notice of Allowance from USPTO for GIMOTI®

    SOLANA BEACH, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that it has been granted a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application No. 17/366,829 pertaining to GIMOTI, the first and only FDA-approved nasal formulation of metoclopramide commercially

  • GlobeNewswire

    Evoke Pharma Reports Second Quarter 2023 Financial Results

    40% revenue growth compared to Q1 2023 34% increase in prescription fills compared to Q1 2023 Presented industry-leading real-world healthcare utilization data supporting the benefits of GIMOTI compared to oral metoclopramide at DDW 2023; additional abstracts accepted at future medical conferences SOLANA BEACH, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an

  • GlobeNewswire

    Evoke Pharma and EVERSANA Announce Abstract Acceptance at 2023 American Neurogastroenterology and Motility Society (ANMS) Meeting

    Real-world study that explored the healthcare utilization resource utilization among patients receiving GIMOTI with and without prior treatment with oral metoclopramide Both organizations recognize and support Gastroparesis Awareness Month through continued support of the International Foundation for Gastrointestinal Disorders (IFFGD) SOLANA BEACH, Calif. and CHICAGO, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on trea